A Phase III Study in Subjects With Mild to Moderate Psoriasis.
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A randomized, assessor blind, parallel group, three arms, active and placebo controlled study
with objective to demonstrate therapeutic non-inferiority of AKP02 cutaneous spray
(calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO) versus Enstilar cutaneous foam
(calcipotriol 50 μg/g + betamethasone 0.5 mg/g) in subjects with mild to moderate plaque
psoriasis.